Literature DB >> 27082424

Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.

Martina Puglisi1, Adam Stewart, Parames Thavasu, Michael Frow, Suzanne Carreira, Anna Minchom, Ravi Punwani, Jaishree Bhosle, Sanjay Popat, Jonathan Ratoff, Johann de Bono, Timothy Anthony Yap, Mary O''Brien, Udai Banerji.   

Abstract

OBJECTIVES: We hypothesised that it was possible to quantify phosphorylation of important nodes in the phosphatidylinositol 3-kinase (PI3K) pathway in cancer cells isolated from pleural effusions of patients with non-small cell lung cancer (NSCLC) and study their correlation to somatic mutations and clinical outcomes.
MATERIALS AND METHODS: Cells were immunomagnetically separated from samples of pleural effusion in patients with NSCLC. p-AKT, p-S6K and p-GSK3β levels were quantified by ELISA; targeted next-generation sequencing was used to characterise mutations in 26 genes.
RESULTS: It was possible to quantify phosphoproteins in cells isolated from 38/43 pleural effusions. There was a significant correlation between p-AKT and p-S6K levels [r = 0.85 (95% confidence interval 0.73-0.92), p < 0.0001], but not p-AKT and p-GSK3β levels [r = 0.19 (95% confidence interval -0.16 to 0.5), p = 0.3]. A wide range of mutations was described and p-S6K was higher in samples that harboured at least one mutation compared to those that did not (p = 0.03). On multivariate analysis, p-S6K levels were significantly associated with poor survival (p < 0.01).
CONCLUSION: Our study has shown a correlation between p-AKT levels and p-S6K, but not GSK3β, suggesting differences in regulation of the distal PI3K pathway by AKT. Higher p-S6K levels were associated with adverse survival, making it a critically important target in NSCLC.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27082424     DOI: 10.1159/000444928

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  4 in total

1.  A transcriptional biosensor to monitor single cancer cell therapeutic responses by bioluminescence microscopy.

Authors:  Audrey Champagne; Pallavi Jain; Lauriane Vélot; Julie Riopel; Véronique Lefebvre; Bertrand Neveu; Frédéric Pouliot
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.556

2.  A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.

Authors:  Anna Minchom; Parames Thavasu; Zai Ahmad; Adam Stewart; Alexandros Georgiou; Mary E R O'Brien; Sanjay Popat; Jaishree Bhosle; Timothy A Yap; Johann de Bono; Udai Banerji
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

3.  ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways.

Authors:  Xin-Li Liu; Xu-Tao Zhang; Jin Meng; Hong-Fei Zhang; Yong Zhao; Chen Li; Yang Sun; Qi-Bing Mei; Feng Zhang; Tao Zhang
Journal:  Oncotarget       Date:  2017-04-21

4.  Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.

Authors:  B Basu; M G Krebs; R Sundar; R H Wilson; J Spicer; R Jones; M Brada; D C Talbot; N Steele; A H Ingles Garces; W Brugger; E A Harrington; J Evans; E Hall; H Tovey; F M de Oliveira; S Carreira; K Swales; R Ruddle; F I Raynaud; B Purchase; J C Dawes; M Parmar; A J Turner; N Tunariu; S Banerjee; J S de Bono; U Banerji
Journal:  Ann Oncol       Date:  2018-09-01       Impact factor: 32.976

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.